Oncotarget

In The News - Press Releases



Oncotarget | DNA dependent protein kinase (DNA-PK) enhances HIV transcription by promoting RNA polymerase II activity and recruitment of transcription machinery at HIV LTR


FOR IMMEDIATE RELEASE
2020-02-21

Oncotarget Volume 11, Issue 7 | The Research Team has previously reported that DNA-dependent protein kinase facilitates HIV transcription by interacting with the RNA polymerase II complex recruited at HIV LTR.

DNA-PK inhibition/knockdown leads to the severe impairment of HIV replication and reactivation of latent HIV provirus.

Dr. Mudit Tyagi from the Center for Translational Medicine at Thomas Jefferson University, the Division of Infectious Diseases in the Department of Medicine at George... continue reading >>



Oncotarget | Mifamurtide and TAM-like macrophages: effect on proliferation, migration, and differentiation of osteosarcoma cells


FOR IMMEDIATE RELEASE
2020-02-20

Oncotarget Volume 11, Issue 7 | The research team analyzed the effects of Mifamurtide on macrophage polarization and on MG63 proliferation, migration, and differentiation, evaluating the expression of M1/M2 and osteoblast markers and molecules involved in metastasis and proliferation pathways.

Their data suggest that Mifamurtide, switching macrophage polarization towards a TAM-like intermediate M1/M2 phenotype, may modulate the delicate balance between pro-inflammatory and immunomodulatory... continue reading >>



Oncotarget | MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21Cip1


FOR IMMEDIATE RELEASE
2020-02-19

Oncotarget Volume 11, Issue 7 reported that to investigate the mechanisms of these oncogenic functions, the researchers performed gene expression profiling of p53 wild-type human myeloma cell lines after MAGE-A knockdown, which identified a set of 201 differentially expressed genes associated with apoptosis, DNA repair, and cell cycle regulation.

Comparative analysis of Co MMpass subjects based on high or low MAGEA3 expression revealed a set of 6748 DEG that also had significant functional... continue reading >>



Oncotarget | A randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma


FOR IMMEDIATE RELEASE
2020-02-18

Oncotarget Volume 11, Issue 7 features Figure 4, "Exploratory biomarkers," by Boyé, et al.

The objective of this study was to compare the safety and antitumor activity of F14512 and etoposide phosphate in dogs with spontaneous non-Hodgkin lymphoma and to investigate the potential benefit of F14512 in P-glycoprotein overexpressing lymphomas.

Subgroup analysis of dogs with Pgp-overexpressing NHL showed a significant improvement in PFS in dogs treated with F14512 compared with etoposide... continue reading >>



Oncotarget | Risk factors for breast cancer brain metastases: a systematic review


FOR IMMEDIATE RELEASE
2020-02-18

Oncotarget Volume 11, Issue 6 reported that A systematic literature search of EMBASE and MEDLINE was conducted to elucidate the current state of knowledge on known and novel prognostic factors associated with 1) the risk for BCBM and 2) the time to brain metastases (TTBM).

Of these, 69 studies reported risk factors of BCBM, 46 factors associated with the TTBM and twenty studies examined variables for both outcomes.

Young age, estrogen receptor negativity, overexpression of human epidermal... continue reading >>



Oncotarget | Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies


FOR IMMEDIATE RELEASE
2020-02-14

Oncotarget Volume 11, Issue 6 reported that multivariate regression analysis including the two variables of tumor mutation burden and ICB, and their interaction term, showed favorable survival associated with ICB, unfavorable survival associated with TMB without ICB treatment, and improved outcome with increasing TMB in ICB treated patients.

Tumor TP53 mutation was associated with worse survival, but these patients still benefited from ICB.

Dr. Russell R. Broaddus from the Department of... continue reading >>



Oncotarget | The interplay of CDK4 and CDK6 in melanoma


FOR IMMEDIATE RELEASE
2020-02-14

Sh RNA knockdown of either CDK4 or CDK6 significantly reduces cell proliferation and impedes their migratory capacity in vitro, which translates into a strong inhibition of tumor growth in xenotransplantation experiments.

CDK6 knockdown in melanoma cell lines impairs VEGF-A expression and reduces the potential stimulation of endothelial cell growth.

Bioinformatic analysis of human melanoma patient data verifies the key role of CDK6 in tumor angiogenesis in melanoma.

Dr. Karoline Kollmann... continue reading >>



Oncotarget | In vitro studies on CNGRC-CPG2 fusion proteins for ligand-directed enzyme prodrug therapy for targeted cancer therapy


FOR IMMEDIATE RELEASE
2020-02-13

Oncotarget Volume 11, Issue 6 reported in a recent research paper that in vitro binding assays of the purified constructs showed that both X-CPG2 and X-CPG2-X bound with high affinity to cancer cells expressing high levels of APN, compared to their binding to cells expressing low levels of APN. Further in vitro studies of the constructs to assess the therapeutic potential of LDEPT were carried out using cells expressing high and low levels of APN.

Dr. Sayed K. Goda from the Cairo University,... continue reading >>



Oncotarget | Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma


FOR IMMEDIATE RELEASE
2020-02-12

Oncotarget Volume 11, Issue 4: The use of xenografts in immunodeficient mice prevent assessing important clinical aspects of this therapy such as the anti adenovirus immune response or the possible intratumoral immune changes, both of tumor infiltrating leukocytes and of the microenvironment.

However, the presence of circulating anti adenovirus antibodies did not prevent changes detected at the tumor masses: increased infiltration and changes in the quality of immune cells per unit of tumor... continue reading >>



Human insulin modulates α-synuclein aggregation via DAF-2/DAF-16 signalling pathway by antagonising DAF-2 receptor in C. elegans model of Parkinson's disease


FOR IMMEDIATE RELEASE
2020-02-12

The aggregation was increased when DAF-16 was knocked-down independently or along with a co-treatment of human insulin and decreased when DAF-2 was knocked-down independently or along with a co-treatment of Hum INS; whereas Hum INS treatment per se, reduced the aggregation.

The author's results depicted that Hum INS decreases -synuclein aggregation via DAF-2/DAF-16 pathway by acting as an antagonist for the DAF-2 receptor.

Dr. Aamir Nazir from the Division of Neuroscience and Ageing Biology... continue reading >>



Empty SV40 capsids increase survival of septic rats by eliciting numerous host signaling networks that participate in a number of systemic functions


FOR IMMEDIATE RELEASE
2020-02-11

The cover for issue 6 of Oncotarget features Figure 3, "The effect of NCs treatments on routine lab results during disease and recovery progress," by Ben-Nun-Shaul, et al.

Numerous previous attempts to develop therapeutic treatments, directed at discreet targets of the sepsis cascade, could not cope with the complex pathophysiology of sepsis and failed.

Studies in a severe rat sepsis model showed that pre-treatment by NCs led to a dramatic increase in survival, from zero to 75%.

Further... continue reading >>



Oncotarget | Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas


FOR IMMEDIATE RELEASE
2020-02-11

Oncotarget Volume 11, Issue 5: Trop-2 expression was evaluated in 10 formalin-fixed-paraffined-embedded CS by immunohistochemistry and 9 primary CS cell-lines by flow-cytometry.

One Trop-2 low/negative and two Trop-2 positive cell-lines were tested in cell-viability assays.

Trop-2 positive cell-lines showed higher sensitivity to SG in vitro when compared to Trop-2 low/negative cell lines.

Dr. Alessandro D. Santin from the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale ... continue reading >>



Oncotarget | Calcitriol and non-calcemic vitamin D analogue, 22-oxacalcitriol, attenuate developmental and pathological choroidal vasculature angiogenesis ex vivo and in vivo


FOR IMMEDIATE RELEASE
2020-02-10

Oncotarget Volume 11, Issue 5: Here, the author's aim was to validate the ocular anti-angiogenic activity of biologically active vitamin D, calcitriol, and selected vitamin D analogue, 22-oxacalcitriol.

Calcitriol induced a significant reduction in ex vivo mouse choroidal fragment sprouting.

Viability studies in a human RPE cell line suggested non-calcemic vitamin D analogues including 22-oxacalcitriol have less off-target anti-proliferative activity compared to calcitriol and other analogues.... continue reading >>



Oncotarget | Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib


FOR IMMEDIATE RELEASE
2020-02-10

Oncotarget Volume 11, Issue 5: The expression levels of the identified kinases were investigated on RNA and protein level in 200 classified tumor samples from patients, who had undergone gastrectomy, but had received no treatment.

Levels of FRK, DDR1 and SRC expression on both mRNA and protein levels were significantly higher in metastatic patient samples regardless of the tumor stage, while expression levels of SIK2 correlated with tumor size.

Dr. Raquel Carvalho Montenegro from the Drug... continue reading >>



Oncotarget | Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study


FOR IMMEDIATE RELEASE
2020-02-07

Oncotarget Volume 11, Issue 4: Chemotherapy, alone or combined with radiotherapy, is commonly used mostly as palliative treatment; moreover, its poor safety profile limits its use most of the time, especially in elderly patients.

Fifty-eight patients received cetuximab as monotherapy.

The median PFS and OS were 9.7 months and 17.5 months, respectively.

Fifty-one patients experienced toxicity, and 67 adverse events related to cetuximab occurred.

Dr. Henri Montaudié from the Department of... continue reading >>



Oncotarget | Sphingomyelin phosphodiesterase 3 methylation and silencing in oral squamous cell carcinoma results in increased migration and invasion and altered stress response


FOR IMMEDIATE RELEASE
2020-02-07

Oncotarget Volume 11 Issue 5: While lentivirus-induced overexpression of SMPD3 in cell models of oral dysplasia and OSCC did not significantly alter proliferation, it did decrease migration and invasion and increased resistance to the epidermal growth factor receptor inhibitor erlotinib.

These results suggest that SMPD3 downregulation is a common event in OSCC progression and may promote the spread of tumor cells.

Dr. Cathie Garnis from the Department of Integrative Oncology at British... continue reading >>



Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer


FOR IMMEDIATE RELEASE
2020-02-06

Oncotarget Volume 11, Issue 4: In this study, locally advanced head and neck cancer patients undergoing definitive chemoradiation were randomly allocated to weekly cisplatin - radiation {CRT arm} or nimotuzumab -weekly cisplatin -radiation {NCRT arm}.

An interaction test was performed between the study arms and HPV status prior to doing any HPV specific analysis for each of the studied outcomes.

We had 187 HPV negative oropharyngeal cancers, 91 in the CRT arm and 96 in NCRT arm.

The addition ... continue reading >>



Oncotarget | FOXL2 homozygous genotype and chromosome instability are associated with recurrence in adult granulosa cell tumors of the ovary


FOR IMMEDIATE RELEASE
2020-02-06

Oncotarget Volume 11, Issue 4: The present study focused on the influence of the FOXL2 genotype and copy number variations in recurrence by comparing the primary tumor with recurrent lesions in the same patient.

The authors also observed that three recurrent tumors and one primary tumor appeared to be homozygous for the FOXL2 c.402C>G mutation.

Despite the small number of matching primary and recurrent tumors analyzed here, the present study is the first to have shown that the FOXL2... continue reading >>



Oncotarget | Inhibition of fibroblast secreted QSOX1 perturbs extracellular matrix in the tumor microenvironment and decreases tumor growth and metastasis in murine cancer models


FOR IMMEDIATE RELEASE
2020-02-05

Oncotarget Volume 11, Issue 4: Extracellular matrix plays an important role in tumor development and dissemination, but few points of therapeutic intervention targeting ECM of the tumor microenvironment have been exploited to date.

Based on this finding and the increased QSOX1 expression in the stroma of aggressive breast carcinomas, we developed monoclonal antibody inhibitors with the aim of preventing QSOX1 from participating in pro-metastatic ECM remodeling.

Here the authors show that... continue reading >>



Tumor secreted ANGPTL2 facilitates recruitment of neutrophils to the lung to promote lung pre-metastatic niche formation and targeting ANGPTL2 signaling affects metastatic disease


FOR IMMEDIATE RELEASE
2020-02-05

Oncotarget Volume 11, Issue 5: The authors determined that tumor-derived ANGPTL2 stimulates lung epithelial cells, which is essential for primary tumor-induced neutrophil recruitment in lung and subsequent pre-metastatic niche formation.

Lastly, they identified that a p63 isoform, Np63, drives a high level of ANGPTL2 secretion and pharmaceutical inhibition of ANGPTL2 signaling by a non-RGD-based integrin-binding peptide diminished metastatic load in lungs likely due to reduction of the lung... continue reading >>



Overall survival in patients with lung adenocarcinoma harboring "niche" mutations: an observational study


FOR IMMEDIATE RELEASE
2020-02-04

The cover for issue 5 of Oncotarget features Figure 2, "Survival curves in the KRAS, EGFR, and niche mutations cohorts," by Aramini, et al.

Mutations were observed in all genes studied, except c-MET, DDR2, MAP2K1, and RET.

The multivariable analysis showed that:

  1. Niche mutations had higher mortality than EGFR mutations
  2. KRAS mutations had higher mortality than EGFR mutations, and
  3. Niche mutations presented similar mortality to KRAS mutations.

Niche mutations exhibited an increased risk of... continue reading >>



Clostridium perfringens enterotoxin induces claudin-4 to activate YAP in oral squamous cell carcinomas


FOR IMMEDIATE RELEASE
2020-02-03

Oncotarget Volume 11, Issue 4: Treatment of human oral squamous cell carcinoma cell lines HSC3 and HSC4 with Clostridium perfringens enterotoxin, induced CLDN4 nuclear translocation to enhance epithelial-mesenchymal transition, stemness, cell proliferation, and invasive ability.

Moreover, it was revealed that the complex of YAP1, CLDN4, and zona occludens-2 was formed by CPE treatment, further suppressing YAP1 phosphorylation by LATS1 and activating it.

Dr. Yi Luo from the Key Laboratory of... continue reading >>



Anti-carcinoembryonic antigen-related cell adhesion molecule antibody for fluorescence visualization of primary colon cancer and metastases in patient-derived orthotopic xenograft mouse models


FOR IMMEDIATE RELEASE
2020-01-31

Oncotarget Volume 11, Issue 4: The research team's aim was to investigate mAb 6G5j binding characteristics and to validate fluorescence targeting of colorectal tumors and metastases in patient derived orthotopic xenograft models with fluorescently labeled 6G5j.

Nude mice received orthotopic implantation of patient-derived primary colon cancer and patient-derived colon cancer metastases.

Anti-CEACAM antibody 6G5j binds multiple CEACAMs which may lead to improved detection of tumor margins for... continue reading >>



Chemical modulation of autophagy as an adjunct to chemotherapy in childhood and adolescent brain tumors


FOR IMMEDIATE RELEASE
2020-01-31

The cover for issue 81 of Oncotarget features Figure 1, "Molecular Mechanisms of Autophagy," by Servante, et al.

On one face, especially in the early phases of cancer formation, autophagy can act as a cellular housekeeper to eliminate damaged organelles and recycle macromolecules, thus acting as tumor suppressor. The researchers present an overview of the relevance of autophagy in central nervous system tumors including how its chemical modulation can serve as a useful adjunct to... continue reading >>



Inherited DNA-repair gene mutations in African American men with prostate cancer


FOR IMMEDIATE RELEASE
2020-01-30

Oncotarget Volume 11, Issue 4: Pathogenic or likely pathogenic alterations in these 14 DNA repair genes were less likely to be detected in African Americans as compared to Caucasians.

Upon a more in-depth analysis, the risk of germline pathogenic/likely pathogenic BRCA mutations was similar between the two populations whereas there was a lower risk among African Americans for the non-BRCA mutations.

Dr. Oliver Sartor from the Tulane Cancer Center at the Tulane University of School of Medicine ... continue reading >>



Characterization of unique PMEPA1 gene splice variants (isoforms d and e) from RNA Seq profiling provides novel insights into the prognostic evaluation of prostate cancer


FOR IMMEDIATE RELEASE
2020-01-29

The cover for issue 4 of Oncotarget features Figure 8, "Model for biological function categorization of PMEPA1 isoforms (c, d, and e) in the context of prostate cancer," by Sharad, et al.

In addition to 4 reported PMEPA1 isoforms, one novel isoform PMEPA1-e was identified with RNA Seq analysis of hormone-responsive VCa P, LNCa P cells and human prostate cancer samples from The Cancer Genome Atlas dataset.

The researchers analyzed the structures, expressions, biological functions and clinical... continue reading >>



Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O6-methylguanine-DNA methyltransferase with a double arm hybrid molecule


FOR IMMEDIATE RELEASE
2020-01-28

The cover for issue 80 of Oncotarget features Figure 5, "Molecular modeling of MR30," by Rupp, et al.

In order to block uncoupled events associated with EGFR and MGMT, the research team designed MR30, a single molecule termed combi-molecule that contains a quinazoline arm targeted to EGFR and an O6-benzylguanine moiety to block MGMT. Molecular analysis of the mechanism of action of its two arms showed that: it could block EGFR phosphorylation, down-regulate the RAF-MAPK and the PI3K-AKT... continue reading >>



Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy


FOR IMMEDIATE RELEASE
2020-01-27

The cover for issue 78 of Oncotarget features Figure 4, "Effect of FKBP51 KO on glucocorticoid response and Akt/mTOR in HaCaT human keratinocytes," by Baida, et al.

Here, the researchers used FKBP51 knockout mice to determine FKBP51s role in the major adverse effect of topical glucocorticoids, skin atrophy. Furthermore, despite the absence of inhibitory FKBP51, the basal level of expression and glucocorticoid activation of GR target genes were not increased in FKBP51 KO skin or... continue reading >>



In preclinical study, the phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts


FOR IMMEDIATE RELEASE
2020-01-24

Prof. Malka Cohen-Armon and her team at Tel Aviv University's Sackler Faculty of Medicine choose Oncotarget for a third time amongst leading medical journals like The New England Journal of Medicine, Nature or The Lancet to publish groundbreaking preclinical cancer research.

Here's more: Recent reports demonstrate an exclusive eradication of a variety of human cancer cells by the modified phenanthridine PJ34. The efficient eradication of malignant cells in human pancreatic cancer xenografts... continue reading >>



Oncotarget | The virome of HPV-positive tonsil squamous cell carcinoma and neck metastasis


FOR IMMEDIATE RELEASE
2020-01-23

Oncotarget Volume 11, Issue 3 features Figure 3, "Hierarchical clustering of tonsil squamous cell carcinoma cohorts based on viral signature detection pattern with associated pathological features (perineural invasion (PNI), lymphovascular invasion (LVI), and tumor stage (T stage))," by Carey, et al.

In this prospective study, a pan-pathogen microarray was used to determine the virome of early stage, p16-positive OPSCC and neck metastasis treated with transoral robotic surgery and neck... continue reading >>



RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models


FOR IMMEDIATE RELEASE
2020-01-22

The cover for issue 71 of Oncotarget features Figure 1B, "Schematic representation to illustrate the differential binding and internalization of low affinity EGFR-ADC on normal cells versus tumor cells that express higher level of the receptors," by Wong, et al.

Potent in vitro cytotoxicity of RN765C, with nanomolar to subnanomolar EC50, was observed on a panel of cancer cell lines expressing moderate to high level of EGFR. Mechanistically, RN765C has multiple modes of action: inducing payload ... continue reading >>



Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer


FOR IMMEDIATE RELEASE
2020-01-20

The cover for issue 70 of Oncotarget features Figure 4B, "BRAF/MEK inhibitor-based phase 1 trial therapy according to BRAF or KRAS hotspot mutation status," by Wang, et al.

About 10%, 18%, 36%, and 36% of the patients had metastatic KRAS+/TP53+, KRAS+/TP53-,KRAS-/TP53+, and KRAS-/TP53- NSCLC, respectively. Introduction of the evolutionary action score system of TP53 missense mutations enabled the research team to identify a subgroup of NSCLC patients with low-risk mutant p53 proteins having a ... continue reading >>



mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs


FOR IMMEDIATE RELEASE
2020-01-17

The cover for issue 69 of Oncotarget features Figure 5, "qRT-PCR analysis of select mRNAs in mTORC1/2 inhibited cells with and without carboplatin treatment," by David-West, et al.

Using platinum-resistant OVCAR-3 cells treated with the selective mTORC1/2 inhibitor INK128/MLN128, the research team conducted genome-wide transcription and translation studies and analyzed the effect on cell proliferation, AKT-mTOR signaling and cell survival, to determine whether carboplatin resistance involves... continue reading >>



Bladder cancer detection by urinary extracellular vesicle mRNA analysis


FOR IMMEDIATE RELEASE
2020-01-16

The cover for issue 67 of Oncotarget features Figure 4, "ROC curve analysis of urinary EV mRNA markers in various stages of bladder cancer," by Murakami, et al.

Biomarker candidates were identified through RNA-seq analysis of urinary EV from patients with non-muscle invasive bladder cancer, advanced urothelial cancer, no residual tumor after TURBT, and healthy and disease controls. These genes allowed detection of non-muscle invasive bladder cancer as well as pT2 and higher muscle invasive... continue reading >>



Tumor cell density regulates matrix metalloproteinases for enhanced migration


FOR IMMEDIATE RELEASE
2020-01-15

The cover for issue 66 of Oncotarget features Figure 4, "RNA sequencing of PDX tumors," by Jayatilaka, et al.

Cancer cell density changes dramatically during the early growth of a primary tumor and during the early seeding steps of secondary tumors and has been implicated in playing an important role in regulating metastasis and drug resistance. Local tumor cell density also plays a role in the responsiveness of cells to matrix metalloproteinases inhibitors, such as Batimastat, Marimastat,... continue reading >>



The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma


FOR IMMEDIATE RELEASE
2020-01-14

The cover for issue 2 of Oncotarget features Figure 5, "MASPIN can prevent the formation of UPA - UPA-receptor complex by a single step, and thus decrease the possibility of the abnormal degradation of the ECM, the development metastasis and angiogenesis," by Fodor, et al.

In the present study, the research team investigated AEZS-108 induced cytotoxicity and the altered mRNA expression profile of regulatory factors related to angiogenesis and metastasis in LHRH receptor-positive OCM3 cells.

Th... continue reading >>



Genomic mutations and histopathologic biomarkers in Y90 radioembolization for chemorefractory colorectal liver metastases


FOR IMMEDIATE RELEASE
2020-01-13

The cover for issue 65 of Oncotarget features Figure 5, "Waterfall plot showing response by % change in tumor size after Y-90 radioembolization," by Dendy, et al.

To investigate mutational load and histologic biomarkers as prognostic factors in patients with chemorefractory colorectal liver metastases treated with Y-90 radioembolization therapy. Single institution retrospective study of patients with CRLM who received Y-90 radioembolization after undergoing molecular testing was performed.... continue reading >>



RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue


FOR IMMEDIATE RELEASE
2020-01-10

The cover for issue 64 of Oncotarget features Figure 2, "Principal component analysis based on gene expression," by Forster, et al.

While standard RNA expression tests stratify patients into risk groups, RNA-Seq can guide personalized drug selection based on expressed mutations, fusion genes, and differential expression between tumor and normal tissue. This research identified breast cancer related and drug related genes that are expressed uniformly across our normal samples.

Normal... continue reading >>



PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients


FOR IMMEDIATE RELEASE
2020-01-09

The cover for issue 62 of Oncotarget features Figure 3, "High tumor load is associated with increased number of CD8+EOMEShigh T betlow cells," by Sponaas, et al.

Here, the researchers found similar proportions of PD1+ CD8+ T cells and similar levels of PD1 expression on CD8+ T cells in the bone marrow of myeloma patients and healthy controls. PD1 expression on CD8+ T cells did not correlate with tumor load suggesting that at least some of the PD1+ CD8+ T cells were specific for non-myeloma... continue reading >>



Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer


FOR IMMEDIATE RELEASE
2020-01-08

The cover for issue 60 of Oncotarget features Figure 8, "Modeling of palbociclib resistance in KRAS-mutant NSCLC cells and effects of MAP kinase pathway inhibition," by Haines, et al.

The research demonstrates that KRAS-mutant NSCLC cell lines are initially sensitive to the CDK4/6 inhibitor palbociclib, but readily acquire resistance associated with increased expression of CDK6, D-type cyclins and cyclin E. Resistant cells also demonstrated increased ERK1/2 activity and sensitivity to MEK and... continue reading >>



Identification of signature genes associated with therapeutic resistance to anti-VEGF therapy


FOR IMMEDIATE RELEASE
2020-01-07

The cover for issue 1 of Oncotarget features Figure 5, "APLN overexpression correlates with worsened prognosis in ovarian cancer patients treated with bevacizumab," by Jaiprasart, et al.

To establish a molecular signature of this resistance in ovarian cancer, the authors developed preclinical tumor models of adaptive resistance to chronic anti-VEGF treatment.

These findings link signature gene expressions with anti-VEGF response, and may thus provide novel targetable mechanisms of clinical... continue reading >>



High AGR2 protein is a feature of low-grade endometrial cancer cells


FOR IMMEDIATE RELEASE
2020-01-06

The cover for issue 59 of Oncotarget features Figure 4, "The expression of AGR2 in metastatic lesions," by Kamal, et al.

Elevated AGR2 protein expression-scores were associated with a high expression of estrogen alpha, progesterone, androgen receptors and early clinical stages. High-AGR2 protein levels were associated with better overall survival in all ECs, but in highly-ER -expressing ECs, AGR2 associated with unfavorable patient outcome. The association between high AGR2 and progressive... continue reading >>



Chromatin-associated APC regulates gene expression in collaboration with canonical WNT signaling and AP-1


FOR IMMEDIATE RELEASE
2020-01-03

The cover for issue 58 of Oncotarget features Figure 7, "Models of WNT-mediated transcriptional activation and repression involving TCF7L2, AP-1, β-catenin and APC," by Hankey, et al.

The APC protein performs multiple tumor suppressor functions including negative regulation of the canonical WNT signaling pathway by both cytoplasmic and nuclear mechanisms. Published reports that APC interacts with -catenin in the chromatin fraction to repress WNT-activated targets have raised the possibility... continue reading >>



Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers


FOR IMMEDIATE RELEASE
2020-01-02

The cover for issue 57 of Oncotarget features Figure 1A, "Schematic representation of our systematic approach developed to identify effective compounds and biological vulnerabilities in EwS.," by Tsafou, et al.

The research group identified differential sensitivities of Ewing sarcoma cells to BCL-2 family inhibitors dependent on the EWS-FLI1 regulome including altered MCL-1 expression and subcellular localization. This study facilitates the selection of effective targeted approaches for future ... continue reading >>



Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses


FOR IMMEDIATE RELEASE
2019-12-31

The cover for issue 68 of Oncotarget features Figure 4, "Gene expression changes to the TME demonstrate sequential development of innate and adaptive immune responses," by Leong, et al.

Intratumoral injection of SD-101 induces significant anti-tumor immunity in preclinical and clinical studies, especially when combined with PD-1 blockade.

Combination therapy generated CD8+ T cell dependent immunity leading to rejection of both non-injected and injected tumors and long-term survival, even in... continue reading >>



Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models


FOR IMMEDIATE RELEASE
2019-12-30

The cover for issue 75 of Oncotarget features Figure 7, "Antitumor efficacy of anetumab ravtansine in combination with bevacizumab in human ovarian cancer xenograft models in mice," by Quanz, et al.

Herein, the research team investigated the antitumor efficacy of the mesothelin-targeting antibody-drug conjugate anetumab ravtansine as a novel treatment option for ovarian cancer in monotherapy and in combination with the antitumor agents pegylated liposomal doxorubicin, carboplatin, copanlisib... continue reading >>



Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma


FOR IMMEDIATE RELEASE
2019-12-27

The cover for issue 72 of Oncotarget features Figure 5A, "Elevated levels of secreted LIF negatively correlates with lymphocyte infiltration in human OAC pre-treatment biopsies," by Buckley, et al.

Inflammation influences OAC given the increased risk of cancer development and poor outcome for obese patients where altered secretion of adipokines and cytokines from adipose tissue contributes a pro-tumourigenic environment. Furthermore, significantly higher circulating levels of LIF were present ... continue reading >>



Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion


FOR IMMEDIATE RELEASE
2019-12-24

The cover for issue 67 of Oncotarget features Figure 1, "Examples of (A) negative, (B) weak, (C) moderate and (D) strong BAP1 staining in prostate cancer and (E) BAP1 staining of cancerous (Ea) and normal (Eb) prostate glands in the same TMA spot," by Steurer, et al.

Studies on the expression and prognostic role of BAP1 in prostate cancer are currently lacking.

The research team used a tissue microarray of 17,747 individual prostate cancer samples linked with comprehensive pathological,... continue reading >>



Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation


FOR IMMEDIATE RELEASE
2019-12-23

The cover for issue 73 of Oncotarget features Figure 2, "Benefit of CAD in TZ tumor identification," by Gaur, et al.

For prostate cancer detection on prostate multiparametric MRI, the Prostate Imaging-Reporting and Data System version 2 and computer-aided diagnosis systems aim to widely improve standardization across radiologists and centers.

Dr. Baris Turkbey from the Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA said "Men with... continue reading >>



Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents


FOR IMMEDIATE RELEASE
2019-12-20

The cover for issue 74 of Oncotarget features Figure 4, "Treatment interruptions and dose modifications," by Jordan, et al.

Mean AE totals for CCs or MTAs respectively was 4.7 versus 3.0 in cycle 1, 3.8 versus 2.8 in cycles 2-6.Patients on CCs had higher mean AEs in six cycles compared to those on MTAs. For MTAs, more frequent incidence of first grade 3/4 AEs after cycle 1 supports incorporation of delayed AEs into recommendations for Phase 2 dosing.

Dr. Debashis Sarker from the School of... continue reading >>



A small molecule regulator of tissue transglutaminase conformation inhibits the malignant phenotype of cancer cells


FOR IMMEDIATE RELEASE
2019-12-18

The cover for issue 76 of Oncotarget features Figure 2, "The identification of TTGM 5826 as a potential modulator of tTG conformation," by Katt, et al.

This raises the possibility that strategies directed toward causing tTG to maintain an open state could potentially provide a therapeutic benefit for cancers in which tTG is highly expressed. Thus, TTGM 5826 represents the lead compound for a new class of small molecules that promote the toxicity of cancer cells by stabilizing the open state of ... continue reading >>



Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer


FOR IMMEDIATE RELEASE
2019-12-17

The cover for issue 66 of Oncotarget features Figure 1, "HD-SCA sample processing and CRC analysis overview," by Gerdtsson, et al.

The research team has established an approach for measuring patient-specific circulating and solid cell concordance by introducing tumor touch preparations to the High-Definition Single Cell Analysis workflow for high-resolution cytomorphometric characterization of metastatic colorectal cancer.

Combined with the association of circulating cells with tumor burden... continue reading >>



Loss of KIBRA function activates EGFR signaling by inducing AREG


FOR IMMEDIATE RELEASE
2019-12-16

The cover for issue 52 of Oncotarget features Figure 5, "Low KIBRA expression predicts poor breast cancer patient outcome," by Mussell, et al.

The clinical significance of KIBRA deregulation and the underlying mechanisms by which KIBRA regulates breast cancer initiation and progression remain poorly understood. Mechanistically, the researchers observed that inhibiting KIBRA induced growth factor-independent cell proliferation in 2D and 3D culture due to the secretion of amphiregulin, an... continue reading >>



Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure


FOR IMMEDIATE RELEASE
2019-12-12

The cover for issue 87 of Oncotarget features Figure 1, "The survival rate of genetically engineered mice with pancreatic ductal adenocarcinoma treated with a weekly injection of nano-albumin bound paclitaxel (NAB-paclitaxel) alone (orange line, n = 4), NAB-paclitaxel 3 hours after CYT-6091 treatment (green line, n = 4), and vehicle control (blue line, n = 3)," by Libutti, et al.

Although a number of new systemic therapeutic options in patients with advanced solid cancers have emerged due to... continue reading >>



Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans


FOR IMMEDIATE RELEASE
2019-12-11

This was a retrospective review of a cohort of patients that were profiled using established IHC biomarkers, along with fragment analysis, in situ hybridization and sequencing.

Their treatments were either matched or unmatched based on whether the treatment chosen by their physician was predicted to be beneficial by Caris Life Sciences using the molecular profile of the tumor.

Comparing these two groups showed that the matched treatment group had an increase of 31% in survival compared to the ... continue reading >>



Dynamic changes during the treatment of pancreatic cancer


FOR IMMEDIATE RELEASE
2019-12-10

This detailed analysis of the clinical descriptions, imaging, pathology, molecular and cellular evolution of the tumors, treatments and responses to chemotherapy, targeted therapies and immunotherapies as well as attempts at the development of personalized medical treatments for a single patient should provide a valuable guide to future directions in cancer treatment.

"They all sacrificed time and effort from other research projects and activities, because they all came to appreciate the... continue reading >>



Modulation of proliferation factors in lung adenocarcinoma with an analysis of the transcriptional consequences of genomic EGFR activation


FOR IMMEDIATE RELEASE
2019-12-10

The cover for issue 65 of Oncotarget features Figure 7, "EGFR activated cases compared to pathway markers," by Kucherlapati, et al.

Molecular subtypes based on copy number, DNA methylation, and mRNA expression had variable proliferation levels, the highest correlating with decreased survival.

Significantly, results suggest EGFR over expression and activation are early alterations that likely stall the replication complex through PCNA phosphorylation creating replication stress responsible for ... continue reading >>



Real-time scratch assay reveals mechanisms of early calcium signaling in breast cancer cells in response to wounding


FOR IMMEDIATE RELEASE
2019-12-09

The connections between mechanically-activated ATP signaling, purinergic receptors, calcium signaling, and EMT in vitro cancer biology are mounting, but are still not well-defined.

Dr. Stephen J.P. Pratt and Dr. Stuart S. Martin research team said that "By first experimentally defining rapid mechanically-induced calcium signaling in cancer cells, this work sets a foundation to explore mechano-calcium relationships driving malignant progression"

There is growing evidence supporting the notion... continue reading >>



Clinical significance of the correlation between PLCE 1 and PRKCA in esophageal inflammation and esophageal carcinoma


FOR IMMEDIATE RELEASE
2019-12-06

This study analyzed the expression levels of and correlation between PLCE1 and PRKCA in human esophagitis, carcinogen NMBA-induced rat esophagus, PLCE1 genetic deficient mouse esophageal epithelial tissues and human esophageal cancer cell line, integrated with Online oncology data sets.

The research team found that the expression levels of both PLCE1 and PRKCA were significantly elevated in human esophagitis, esophageal squamous cell carcinoma, Barretts esophagus, esophageal adenocarcinoma and ... continue reading >>



NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance


FOR IMMEDIATE RELEASE
2019-12-05

In younger (<60 years old, n = 37) and older patients (>60 years old, n = 47), treatment with HDC/IL-2 resulted in an expansion of CD56bright and CD16+ NK cells in blood along with an increased NK cell expression of the natural cytotoxicity receptors NKp30 and NKp46.

Dr. Anna Martner from the TIMM Laboratory, Sahlgrenska Cancer Center at the University of Gothenburg in Gothenburg, Sweden said, "At diagnosis, approximately 70% of patients with acute myeloid leukemia (AML) are >60 years old.... continue reading >>



Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines


FOR IMMEDIATE RELEASE
2019-12-04

Blood samples obtained during a randomized trial in patients with metastatic melanoma were tested from 22 patients treated with a tumor cell vaccine and 17 treated with a dendritic cell vaccine.

Among DCV-treated patients, these sPD-1 criteria appropriately classified 8/10 of 3-year survivors, and 6/7 of patients who did not survive three years.

Dr. Robert O. Dillman from AIVITA Biomedical, Inc. in Irvine, CA, USA said, "PD-1 (CD279) was first described by Tasuku Honjo and colleagues at Kyoto ... continue reading >>



A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host


FOR IMMEDIATE RELEASE
2019-12-03

The cover for issue 64 of Oncotarget features Figure 5, "In vivo and ex-vivo growth kinetics of B6CaP," by Simons, et al.

The Research Team reports the establishment of B6Ca P, an allograft tumor line from a Hi-Myc transgenic mouse that had been backcrossed onto C57BL/6J background.

This is the first example of a prostate-derived tumor line that shows frequent metastasis to bone and grows in an immunocompetent host, making this model useful for studying mechanisms of bone metastasis and tumor ... continue reading >>



Application of C. elegans cancer screening test for the detection of pancreatic tumor in genetically engineered mice


FOR IMMEDIATE RELEASE
2019-12-03

Previously, the research group developed a novel method to detect various kinds of human cancer using nematode Caenorhabditis elegans that respond to cancer odor in urine; however, whether this method is useful for non-human species remains to be understood.

The chemotactic analysis indicated that C. elegans avoids urine of healthy recipient mice, while they tended to be attracted to urine of mice with Kras G12D. The research team's study demonstrated that C. elegans can recognize the odor of... continue reading >>



PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors


FOR IMMEDIATE RELEASE
2019-12-02

To identify possible causes of resistance to MEK inhibition, this research team generated a model of resistance by long-term treatment of AML cells with AZD6244.

Remarkably, resistance to MEK inhibition was due to acquired PTEN haploinsufficiency, rather than mutation of MEK.

Dr. Andrew S. Moore from the University of Queensland Diamantina Institute and the Child Health Research Centre at the University of Queensland in Woolloongabba, Australia as well as the Oncology Services Group at... continue reading >>



CLCA4 inhibits bladder cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT pathway


FOR IMMEDIATE RELEASE
2019-11-27

Overexpression of CLCA4 profoundly attenuated the proliferation, growth, migratory and invasive capabilities of bladder cancer cells, whereas CLCA4 knockdown had the opposite effect.

This study suggests that CLCA4 may represent a promising prognostic biomarker for bladder cancer and provides a possible mechanism for bladder cancer growth and invasion.

Dr. Zhaohui Chen from the Department of Urology, Union Hospital, Tongji Medical College at the Huazhong University of Science and Technology in ... continue reading >>



NOTCH1 signaling in oral squamous cell carcinoma via a TEL2/SERPINE1 axis


FOR IMMEDIATE RELEASE
2019-11-26

The cover for issue 63 of Oncotarget features Figure 6, "Inverse relationship between ETV7 and SERPINE1 in OSCC," by Salameti, et al.

In this study, the research team investigated NOTCH1 mutations in keratinocyte lines derived from OSCC biopsies that had been subjected to whole exome sequencing.

One line, SJG6, was found to have truncating mutations in both NOTCH1 alleles, resulting in loss of NOTCH1 expression.

Overexpression of the NOTCH1 intracellular domain in SJG6 cells promoted cell... continue reading >>



Mutation of the co-chaperone Tsc1 in bladder cancer diminishes Hsp90 acetylation and reduces drug sensitivity and selectivity


FOR IMMEDIATE RELEASE
2019-11-26

The researchers have recently identified the tumor suppressor tuberous sclerosis complex 1 as a new co-chaperone of Hsp90 that affects Hsp90 binding to its inhibitors.

Their findings suggest that TSC1 status may predict response to Hsp90 inhibitors in patients with bladder cancer, and co-targeting HDACs can sensitize tumors with Tsc1 mutations to Hsp90 inhibitors.

Dr. Mehdi Mollapour and Dr. Dimitra Bourboulia said, "Over 80,000 people will be diagnosed with bladder cancer and approximately... continue reading >>



Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study


FOR IMMEDIATE RELEASE
2019-11-25

The aim was to test the feasibility of using cell-free DNA to support evaluation of treatment response, pseudo-progression and whether progression could be found before clinical and/or radiologic progression.

Cf DNA fluctuated during treatment with the highest levels before diagnostic surgery and at progression.

An increase was seen in 3 out of 4 patients at the time of progression while no increase was seen in 3 out of 4 patients without progression.

Dr. Dorte Schou Nørøxe from the... continue reading >>



Elucidating drivers of oral epithelial dysplasia formation and malignant transformation to cancer using RNAseq


FOR IMMEDIATE RELEASE
2019-11-22

To identify markers of early disease, the research team performed RNA sequencing of 19 matched HPV negative patient trios: normal oral mucosa, dysplasia and associated OSCC.

They highlight novel coding and non-coding candidates for involvement in oral dysplasia development and malignant transformation, and speculate on how their findings may guide further translational research into the treatment of oral dysplasia.

Dr. Lucy F. Stead from Precancer Genomics at Leeds Institute of Cancer and... continue reading >>



The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design


FOR IMMEDIATE RELEASE
2019-11-21

The research shows that the resulting oxadiazole-substituted aza-benzimidazole is a potent and ligand efficient S6 kinase inhibitor, which blocks the phosphorylation of RPS6 at Ser235/236 in TSC negative HCV29 human bladder cancer cells by inhibiting S6 kinase activity and thus provides a useful tool compound to investigate the function of S6 kinases.

Dr. Rob L.M. van Montfort and Dr. Keith Jones said "The 70 KDa ribosomal S6 kinases (S6K) RPS6KB1 (S6K1) and RPS6KB2 (S6K2) are key effectors of ... continue reading >>



Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy


FOR IMMEDIATE RELEASE
2019-11-20

Targeted therapies aimed at tumor vasculature are utilized in combination with chemotherapy to improve drug delivery and efficacy after tumor vascular normalization.

The research team's data in mouse models indicate that activation of calcineurin-NFAT-TSP1 signaling in endothelial cells plays a critical role in exercise-induced shear stress mediated tumor vessel remodeling.

They show that moderate aerobic exercise with chemotherapy caused a significantly greater decrease in tumor growth than... continue reading >>



Avoidance of apoptotic death via a hyperploid salvage survival pathway after platinum treatment in high grade serous carcinoma cell line models


FOR IMMEDIATE RELEASE
2019-11-19

The cover for issue 62 of Oncotarget features Figure 7, "Proposed model of the hyperploid pathway as a salvage survival strategy regulated by the G2-M checkpoint," by Yeung, et al.

Subpopulations of tumor cells may exhibit diverging behaviors from the bulk tumor due to an alternate stress response that diverts tumor cells from apoptotic death.

In this study, the researcher identified a salvage survival pathway in which G2-arrested tumor cells bypassed apoptosis and progressed through aberrant ... continue reading >>



Consuming cholera toxin counteracts age-associated obesity


FOR IMMEDIATE RELEASE
2019-11-19

Here the research team tested a safe and well-established microbe-based immune adjuvant to restore immune homeostasis and counteract inflammation-associated obesity in animal models.

Taken together, they concluded that oral vaccination with cholera toxin B helps stimulate health-protective immune responses that counteract age-associated obesity.

Dr. Susan E. Erdman from the Division of Comparative Medicine, at the Massachusetts Institute of Technology in Cambridge, MA, United States said, "The... continue reading >>



Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers


FOR IMMEDIATE RELEASE
2019-11-18

While estrogen receptor - + breast cancers express high levels of three anti-apoptotic Bcl-2 family members, pharmacological inhibition of Bcl-2 and/or Bcl-xL fails to induce cell death in ER + breast cancer cell lines, due to rapid and robust Mcl-1 upregulation.

Cells treated with a pharmacological inhibitor of cap-dependent translation, or with the mTORC1 inhibitor RAD001/everolimus, displayed reduced protein levels of Mcl-1 under basal conditions, and failed to upregulate Mcl-1 protein... continue reading >>



Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma


FOR IMMEDIATE RELEASE
2019-11-15

46% of patients with on-treatment disease progression showed acquired RAS mutations, while no RAS mutations were found in the non-progressive subset of patients, indicating that acquisition of RAS mutant clones correlated significantly with clinical resistance.

RAS mutations account for acquired resistance to EGFR-targeting in a substantial proportion of HNSCC patients, even though these tumors are rarely mutated at baseline.

Dr. Mascha Binder from the Department of Oncology and Hematology... continue reading >>



Molecular mechanisms of human IRE1 activation through dimerization and ligand binding


FOR IMMEDIATE RELEASE
2019-11-14

IRE1 autophosphorylation is coupled to RNase activity through formation of a back-to-back dimer, although the conservation of the underlying molecular mechanism is not clear from existing structures.

The researchers have developed a compound that potently inhibits human IRE1 kinase activity while stimulating XBP1 splicing.

A crystal structure of the inhibitor bound to IRE1 shows an increased ordering of the kinase activation loop.

Dr. Richard Bayliss and Dr. Ian Collins said "The endoplasmic ... continue reading >>



Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance


FOR IMMEDIATE RELEASE
2019-11-13

PET-CT scan revealed a space-occupying lesion in the left lung, and the pathologic result confirmed the occupying lesion originated from NPC. Meanwhile, both immunohistochemistry and PCR revealed that the occupying lesion belonged to pMMR NPC. We provide the first report that pembrolizumab has a confirmed objective response to microsatellite stability and pMMR NPC, and two biomarkers may not be sufficient to identify patients who might be resistant to such treatment in NPC.

Dr. Qin Lin from... continue reading >>



High expression of apoptosis protein (Api-5) in chemoresistant triple-negative breast cancers: an innovative target


FOR IMMEDIATE RELEASE
2019-11-12

The cover for issue 61 of Oncotarget features Figure 4, "The influence of stress conditions on API-5 expression and inhibition," by Bousquet, et al.

78 TNBC biopsies from patients with different responses to chemotherapy were analysed for API-5 expression before any treatment.

Further studies on API-5 expression and inhibition were performed on patient-derived TNBC xenografts, one highly sensitive to chemotherapies and the other resistant to most tested drugs.

Clinical analyses of the 78... continue reading >>



Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers


FOR IMMEDIATE RELEASE
2019-11-06

19 of 44 patients treated with genomically guided therapy attained a PFS ratio 1.3 vs. 3 of 57 treated with non-genomically guided therapy.

Similarly, overall PFS ratios were higher for patients with genomically guided therapy vs non-genomically guided therapy.

Patients with refractory metastatic cancer who receive genomically guided therapy have improved PFS ratios and longer median PFS compared to patients who do not receive genomically guided therapy.

Dr. Bryan P. Schneider from the... continue reading >>



Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications


FOR IMMEDIATE RELEASE
2019-11-05

The cover for issue 60 of Oncotarget features Figure 3, "Comparison of cytokine levels grouped by function," by Donnenberg, et al.

Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the Luminex system.

Comparing NSCLC PE and published plasma levels of CAR-T recipients, both were dominated by sIL-6R and IL-6 but NSCLC PE had more VEGF, FGF2 and TNF, and less IL-2, IL-4, IL-13, IL-15, MIP1 and... continue reading >>



Dynamic transition of the blood-brain barrier in the development of non-small cell lung cancer brain metastases


FOR IMMEDIATE RELEASE
2019-10-30

The cover for issue 59 of Oncotarget features Figure 9, "A schematic representation of the blood-brain barrier (BBB), brain around tumor region (BAT) and blood-tumor barrier (BTB) in late stage NSCLC brain metastases in an experimental model," by Uzunalli, et al.

Effective drug delivery through the BTB is one of the greatest therapeutic obstacles in treating brain metastases.

Using an experimental model, the researchers defined key changes within the BTB and the BBB in the brain around the... continue reading >>



Kallikrein 6 protease advances colon tumorigenesis via induction of the high mobility group A2 protein


FOR IMMEDIATE RELEASE
2019-10-22

The cover for issue 58 of Oncotarget features Figure 5, "Representative images of KLK6 and HMGA2 IHC staining in the surgical material of a colon cancer patient," by Chen, et al.

In the CRC patients, KLK6 protein levels were elevated in the non-cancerous distant and adjacent tissues, compared to their paired tumor tissues.

Patients with mutant K-RAS tumors had significantly higher level of KLK6 protein in the luminal surface of non-cancerous distant tissue, compared to the corresponding... continue reading >>



Assessment of circularized E7 RNA, GLUT1, and PD-L1 in anal squamous cell carcinoma


FOR IMMEDIATE RELEASE
2019-10-15

The cover for issue 57 of Oncotarget features Figure 2, "Overall survival analysis of GLUT1, PD-L1, and histologic architecture," by Chamseddin, et al.

High levels of circ E7 by quantitative RT-PCR predicted improved overall survival in ASCC and analysis of The Cancer Genome Atlas sequencing from HPV-positive head and neck cancer and cervical cancer suggested high circ E7 marked improved survival in 875 subjects.

While the research team's study suggests that circ E7 levels correlate with... continue reading >>



Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial


FOR IMMEDIATE RELEASE
2019-10-11

RESILIENT was a single arm, open label, phase II/III study to test if label agnostic therapy regimens guided by Encyclopedic Tumor Analysis can offer meaningful clinical benefit for patients with relapsed refractory metastatic malignancies.

Patients with advanced refractory solid organ malignancies where disease had progressed following 2 lines of systemic treatments were enrolled in the trial.

At study completion, Disease Control was observed in 114 out of 126 patients evaluable per protocol ... continue reading >>



Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma


FOR IMMEDIATE RELEASE
2019-10-05

The authors have developed the Accelera TED platform to repurpose drugs for HNSCC treatment; using in vitro assays and in vivo models.

Screening a library of clinically-approved drugs identified the anti-malarial agent quinacrine as a candidate, which significantly reduced viability in a concentration dependent manner in five HNSCC cell lines and in six primary HNSCC samples.

In vivo, daily treatment with 100 mg/kg oral quinacrine plus cisplatin significantly inhibited tumor outgrowth,... continue reading >>



Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A


FOR IMMEDIATE RELEASE
2019-10-04

Cyclooxygenase-2 is overexpressed in bladder cancer cells, making it an attractive molecular target for the detection and treatment of cancer.

The effects of TKIs on bladder cancer in vivo were evaluated using the COX-2-expressing K9TCC 5Lilly xenograft mouse model and detected by fluorocoxib A. The increased COX-2 expression was detected by all tested TKIs in at least one of the tested COX-2-expressing bladder cancer cell lines in vitro.

Dr. Maria Cekanova from the Department of Small Animal ... continue reading >>



Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay


FOR IMMEDIATE RELEASE
2019-10-03

The assay has a clinically relevant five-day turnaround time and can be conducted on as little as 20 ng genomic DNA with a batch size of up to forty samples in a single run.

Assay performance with respect to accuracy, reproducibility, precision as well as control sample performance was estimated across a wide range of FFPE samples of multiple histologies to address pre-analytical variability, and analytical variability.

Dr. Sean T. Glenn from OmniSeq Inc., Buffalo, NY 14203, USA, the Center... continue reading >>



Safety evaluation of conditionally immortalized cells for renal replacement therapy


FOR IMMEDIATE RELEASE
2019-10-02

Here, the research team assessed the safety of conditionally immortalized proximal tubule epithelial cells for bioartificial kidney application, by using in vitro assays and athymic nude rats.

They demonstrate that these cells do not possess key properties of oncogenically transformed cells, including anchorage-independent growth, lack of contact inhibition and apoptosis-resistance.

Taken together, this study lays an important foundation towards bioartificial kidney development by confirming... continue reading >>



New insights into the genomic landscape of meningiomas identified FGFR3 in a subset of patients with favorable prognoses


FOR IMMEDIATE RELEASE
2019-10-02

The identification of oncogenic mutations has provided further insights into the tumorigenesis of meningioma and the possibility of targeted therapy.

Interestingly, the authors identified a number of mutations in non-NF2 genes, including a hotspot TERTp c.

124: G > A mutation that may be related to poor prognosis and FGFR3 mutations that may represent biomarkers of a favorable prognosis as reported in other cancers.

These mutations can enhance diagnostic accuracy and clinical decision-making.... continue reading >>



Impact of exosomal HIV-1 Tat expression on the human cellular proteome


FOR IMMEDIATE RELEASE
2019-10-02

The cover for issue 54 of Oncotarget features Figure 2, "Comparative proteomic profiling of the peptides/proteins identified from 293T, IL16lamp2b and mExo-Tat samples," by Lu, et al.

The HIV-1 Tat protein is a potent activator of viral transcription.

The researcher's previous work has demonstrated that exosomal formulations of Tat can reverse HIV-1 latency in primary CD4+ T lymphocytes isolated from long term antiretroviral treated individuals suggesting a potential role for Tat as a... continue reading >>



Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma


FOR IMMEDIATE RELEASE
2019-10-02

The cover for issue 55 of Oncotarget features Figure 3, "Romidepsin exhibits anti-tumor effect in xenograft model of DDLPS," by Seligson, et al.

Here the researchers present in silico, in vitro, and mouse xenograft studies that suggest that specifically targeting HDAC2 reduces MDM2 expression and has anti-tumor affects in DDLPS. In a murine DDLPS xenograft model, romidepsin reduced tumor growth and lowered tumor MDM2 expression.

Taken together, their data supports the hypothesis that... continue reading >>



One-bead one-compound combinatorial library derived targeting ligands for detection and treatment of oral squamous cancer


FOR IMMEDIATE RELEASE
2019-09-30

The cover for issue 52 of Oncotarget features Figure 6, "Confocal images of LLY13 peptide-dye conjugates taken up by live cells in culture," by Yang, et al.

By screening combinatorial one-bead one-compound peptide libraries against oral squamous cancer cell lines, two cyclic peptide ligands, LLY12 and LLY13 were previously identified.

In vivo and ex vivo near infra-red fluorescence imaging studies confirmed the in vivo targeting efficiency and specificity of LLY13 in oral cancer orthotopic... continue reading >>



Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy


FOR IMMEDIATE RELEASE
2019-09-22

The cover for issue 53 of Oncotarget features Figure 5, "Preclinical models of Ewing's sarcoma and osteosarcoma respond to DC101 alone and in combination with cytotoxic chemotherapy," by Lowery, et al.

Several pediatric cancer mouse models responded to single agent DC101-mediated VEGFR2 inhibition with tumor growth delay.

The author's data indicate differential efficacy of targeting the VEGFR2 pathway in pediatric models and support the continued evaluation of VEGFR2 inhibition in combination ... continue reading >>



The phosphorylation status of PIP5K1C at serine 448 can be predictive for invasive ductal carcinoma of the breast


FOR IMMEDIATE RELEASE
2019-09-03

The cover for issue 91 of Oncotarget features Figure 6, "PKD1 expression status and phosphorylation of PIP5K1C at S448 correlate in patient samples of TNBC," by Durand, et al.

By comparing normal breast tissue to carcinoma in situ and invasive ductal carcinoma subtypes, Durand et al. show that the phosphorylation status of PIP5K1C at serine residue 448 can be predictive for breast cancer progression to an aggressive phenotype, while PIP5K1C expression levels are not indicative for... continue reading >>



Oridonin inhibits aberrant AKT activation in breast cancer


FOR IMMEDIATE RELEASE
2019-05-15

The cover for issue 35 of Oncotarget features Figure 3, "Surface plasmon resonance (SPR) analysis of Oridonin binding to AKT1," from Sun, et al.

To date pan-or isoform-selective inhibitor of PI3K inhibitors, AKT inhibitors, mTOR inhibitors, and dual PI3K/mTOR inhibitors have not yielded durable or efficacious clinical results, Oridonin offers promise of both increased efficacy and reduced toxicity compared with single PI3K, AKT, or even dual PI3K/mTOR inhibitors.

Dr. Jean J. Zhao... continue reading >>



Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer


FOR IMMEDIATE RELEASE
2019-05-08

Researchers and authors from the Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA hypothesized that mTORC1 inhibition activates the IGF-1R/Ins R/IRS-1/2 axis in an ER-dependent manner to drive PI3K/AKT and promote cancer cell survival, implicating ER in survival signaling induced by mTORC1 inhibition.

"Approximately 70% of primary breast tumors express estrogen receptor and/or progesterone receptor."

In... continue reading >>



Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer


FOR IMMEDIATE RELEASE
2019-05-01

The cover for issue 17 of Oncotarget features Figure 4B, "A comparison of the structural elements comprising human PHGDH, sPHGDH and PHGDH-93. Amino acids involved in hydrogen bond formation to the substrate (*) or cofactor NAD+ (*) are highlighted," from Unterlass, et al.

The compounds identified and characterised in this work are structurally different from the reported PHGDH inhibitors CBR-5884 and NCT-503, and thus provide a new starting point for the design of potent and selective... continue reading >>



Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors


FOR IMMEDIATE RELEASE
2019-04-24

The cover for issue 44 of Oncotarget features Figure 6A, "Autophagy inhibition enables dasatinib to reduce tumour volume in A549 mice xenografts," by Rupniewska, et al.

Taken together, this data suggests that the clinical failure of SRC TKIs in the treatment of NSCLC is due to the induction of intratumoural autophagy by these compounds that prevents apoptosis.

The inhibition of autophagy in combination with classical and targeted chemotherapy is currently the subject of numerous... continue reading >>



Frequently rearranged and overexpressed δ-catenin is responsible for low sensitivity of prostate cancer cells to androgen receptor and β-catenin antagonists


FOR IMMEDIATE RELEASE
2019-04-17

The cover for issue 36 of Oncotarget features Figure 4C, "A cartoon depicts binding complex of catenin proteins and E-cadherin in LNCaP cells, proposed on pull down experiments," from Zhang, et al.

The research shows that δ-catenin in PCa induces β-catenin which, in turn, impacts responses to existing androgen deprivation therapy and currently under development beta-catenin inhibitors.

Dr. Irina V. Kovtun said "Collectively our data suggest that PCa cells with overstimulated δ‐caten... continue reading >>



Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents


FOR IMMEDIATE RELEASE
2019-04-10

The cover for issue 56 of Oncotarget features Figure 1A, "Selinexor reduces the expression of DDR proteins ," by Kashyap, et al.

The goal of this study was to examine the effects of selinexor, an inhibitor of exportin-1 mediated nuclear export, on DNA damage repair and to evaluate the cytotoxic effects of selinexor in combination with DNA damaging agents in cancer cells. In contrast, enhanced cell death was not detected in cells that were pretreated with selinexor then with DDAs. The... continue reading >>



Disulfiram reduces metastatic osteosarcoma tumor burden in an immunocompetent Balb/c or-thotopic mouse model


FOR IMMEDIATE RELEASE
2019-03-28

The cover for issue 53 of Oncotarget features Figure 4, "Image depicting primary (left) and metastatic lung (right) osteosarcoma as visualized by indocyanine green dye angiography," by Crasto, et al.

Disulfiram is an FDA-approved aldehyde dehydrogenase inhibitor that reduces the metastatic phenotype of OS cells in vitro. All treatment groups displayed a significantly reduced quantitative OS metastatic burden compared with controls. Disulfiram treatment resulted in a reduced burden of OS... continue reading >>



Somatic genome alterations in relation to age in lung squamous cell carcinoma


FOR IMMEDIATE RELEASE
2019-03-21

The cover for issue 63 of Oncotarget features Figure 3, "GSEA value of “ECM-Receptor Interaction” pathway in high-SI6/low-SI26 and low-SI6/high-SI26 patient sub-cohorts," by Meucci, et al.

The SNPs mutational profiling showed enrichments of smoking-related signature 4 and defective DNA mismatch repair -related signature 6 in younger patients, while the defective DNA MMR signature 26 was enriched among older patients. We hypothesize that a higher sensitivity to smoking-related damages and ... continue reading >>



Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1


FOR IMMEDIATE RELEASE
2019-03-13

The cover for issue 47 of Oncotarget features Figure 6, "MR-409 down-regulates IGF-1 expression in cancer cells," by Cui, et al.

It is difficult to envision that GHRH could be involved in the pathophysiologic control of IGF-1 secretion since the circulating levels of hypothalamic GHRH are very low.

Nobel Prize winner Dr. Andrew V. Schally from the Veterans Affairs Medical Center and University of Miami, Miami, FL, USA said "This paper describes our investigations of the effects of GHRH... continue reading >>



A diagnostic autoantibody signature for primary cutaneous melanoma


FOR IMMEDIATE RELEASE
2019-03-06

The cover for issue 55 of Oncotarget features Figure 4, "(A) Regression tree diagram of the best combination of the identified autoantibody biomarkers. (B) Cumulative sensitivity and specificity of the 10 AAb biomarker panel. (C) ROC curve and AUC of the biomarker combination in cohort 1," by Zaenker, et al.

To improve early stage melanoma detection, the development of a highly sensitive diagnostic test is of utmost importance. This melanoma autoantibody signature may prove valuable for... continue reading >>



Super-enhancers: novel target for pancreatic ductal adenocarcinoma


FOR IMMEDIATE RELEASE
2019-01-25

The cover for issue 16 of Oncotarget features Figure 6, "Schematic representation of effects of GZ17-6.02 inhibiting SE following tumorigenesis in PDAC," by Ghosh, et al.

Differential H3K27AC marks were identified at enhancer regions of genes including c-MYC, MED1, OCT-4, NANOG, and SOX2 that can act as super-enhancers (SE), cluster of genes in non-cancerous, cancerous and metastatic PDAC cell lines. GZ17-6.02 affects acetylation of the genes, reduces transcription of major transcription ... continue reading >>



Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy


FOR IMMEDIATE RELEASE
2019-01-08

The cover for issue 3 of Oncotarget features images of a research autopsy to characterize clonal heterogeneity in a rare hypermutated cancer, by Chen, et al.

The research team's analyses revealed ultra-hypermutation, defined as >100 mutations per megabase, in this patients cancer, which was further characterized by the presence of three distinct mutational signatures including UV radiation and APOBEC signatures.

Truncal alterations, defined as being present in all clonal tumor cell... continue reading >>



Anti-psychotic drug could treat aggressive breast cancer


FOR IMMEDIATE RELEASE
2018-10-09

The cover for issue 79 of Oncotarget features Figure 8, "Summary figure of proposed pimozide mechanisms," by Dakir, et al.

Full text | Audio Podcast

A commonly-used anti-psychotic drug could also be effective against triple negative breast cancer, the form of the disease that is most difficult to treat, new research has found. The study, led by the University of Bradford, also showed that the drug, Pimozide, has the potential to treat the most common type of lung cancer.

Anti-psychotic drugs ... continue reading >>



ONC201 kills breast cancer cells in vitro by targeting mitochondria


FOR IMMEDIATE RELEASE
2018-05-08

The cover for issue 26 of Oncotarget features Figure 8, "Proposed mechanism of action of ONC201," from Greer, et al.

TRAIL, a member of the TNF family of ligands, causes caspase–dependent apoptosis through activation of its receptors, death receptor 4 and DR5.

ONC201 was originally identified as a small molecule that inhibits both Akt and ERK, resulting in dephosphorylation of Foxo3a and thereby induces TRAIL transcription.

Recently, two independent groups, Wafik El Deiry at Fox Chase and ... continue reading >>



PD-L1 expression in medulloblastoma: an evaluation by subgroup


FOR IMMEDIATE RELEASE
2018-04-30

The cover for issue 27 of Oncotarget features Figure 5, "MYC overexpression in DAOY (YM21) does not alter PD-L1 expression," from Martin, et al.

This study evaluated the expression of PD‐L1 and markers of immune mediated resistance in human medulloblastoma, the most common malignant pediatric brain tumor.

In cell lines, SHH MB, which are low‐MYC expressing, demonstrated both constitutive and inducible expression of PD‐L1 while those in Group 3/4 that expressed high levels of MYC had only... continue reading >>



Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis


FOR IMMEDIATE RELEASE
2018-04-17

The cover for issue 24 of Oncotarget features Figure 1, "Workflow for enumeration of cleaved caspase-3 bleb–positive [CC3(bleb)+] cells in FFPE canine tumor tissue," from Dull, et al.

Existing microscopy-based methods of detecting apoptosis, such as TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling), have limited quantitative capabilities due to insufficient signal-to-noise ratios. Researchers at the National Cancer Institute and National Cancer Institute-Frederick have... continue reading >>



OncoDNA announces publication of peer-reviewed study in Oncotarget assessing the utility of its unique biomarker analysis and interpretation platform in clinical decision making


FOR IMMEDIATE RELEASE
2018-04-17

The cover for issue 29 of Oncotarget features Figure 2, "Categorisation of samples analysed," from Laes, et al.

  • - OncoDNA treatment recommendation followed in 60% of cases
  • - 93% of treatment decisions were made based on a holistic approach combining next generation sequencing (NGS) and multiple biomarker analysis provided by OncoDNA
  • - 27% of late-stage patients treated with OncoDNA-recommended therapies had overall survival >12 months, compared to a typical average of no more than six months
... continue reading >>


Analysis of the 9p21.3 sequence associated with coronary artery disease reveals a tendency for duplication in a CAD patient


FOR IMMEDIATE RELEASE
2018-03-14

The cover for issue 20 of Oncotarget features Figure 1B, "The diagram showing a general scheme of TAR cloning of a region of interest (in red) from total genomic DNA (in blue) with a linearized TAR vector containing a yeast selectable marker HIS3, centromeric sequence from chromosome 6 (CEN6) and two unique targeting sequences (hook1 and hook2) homologous to 5′ and 3′ ends of the targeted region," from Kouprina, et al.

Before a conclusive link between the SDs and the cardiovascular diseases... continue reading >>



Preclinical characterization of therapeutic antibodies targeted at the carboxy-terminus of Sonic hedgehog


FOR IMMEDIATE RELEASE
2018-03-09

The cover for issue 18 of Oncotarget features Figure 1, "Schematic of experimental procedures for generation of novel anti-Sonic Hedgehog (Shh) candidate therapeutic antibodies directed at the carboxy (C)-terminal," from Tolani, et al.

Even though the Shh pathway is mainly quiescent in adults, the safety of Shh-targeting with therapeutic antibodies was questioned initially because not only does the N-terminus of the Shh protein play an important role in embryonic development, but Shh also... continue reading >>



Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs


FOR IMMEDIATE RELEASE
2018-03-09

The cover for issue 15 of Oncotarget features Figure 3, "Costs per patient among the health system health plan members in the last 3 months of life, by site of care," from Haslem, et al.

The use of advanced molecular diagnostic technologies, such as Next-Generation Sequencing based gene panel testing, to select targeted therapies in advanced cancer patients is known as precision oncology.

In order to evaluate the impact of precision cancer medicine beyond the PFS window and to determine the... continue reading >>



Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process


FOR IMMEDIATE RELEASE
2018-03-01

The cover for issue 16 of Oncotarget features Figure 4A, "Circos plots depicting 316 deferentially expressed genes (FDR < 0.1) out of 745 target genes detected by TargetScan for mir-24-3p (differentially expressed in patients with high mir-24-3p levels vs. low miR-24)," from Khodadadi-Jamayran, et al.

Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process

Despite improvements in local, regional and systemic therapies for breast cancer, 40,610... continue reading >>



Oncotarget to be Indexed in Highly Esteemed Meta Database


FOR IMMEDIATE RELEASE
2018-02-21

Oncotarget to be Indexed in Highly Esteemed Meta Database
Chan Zuckerberg Initiative's Meta Database increases accessibility of scientific data around the world

ORCHARD PARK, N.Y. - February 21, 2018 - This week, Oncotarget announced that its peer-reviewed research publications will be indexed in Meta, a world-renowned database comprised of a plethora scientific literature, alongside our other Impact Journal publications. Meta was acquired by the Chan Zuckerberg Initiative in an effort to... continue reading >>



Oncotarget: Cancer pioneer employs physics to approach cancer in last research article


FOR IMMEDIATE RELEASE
2018-02-20

The cover for issue 14 of Oncotarget features "Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem," from Frost, et al.

Oncotarget: Cancer pioneer employs physics to approach cancer in last research article.

Distinguished Professor Donald S. Coffey spent more than 50 years at Johns Hopkins and influenced generations of cancer researchers worldwide.

ORCHARD PARK, New York - (FEBRUARY 20, 2018) - In the cover article of Tuesday's issue of... continue reading >>



Oncotarget awards grants to four biomedical researchers at Frontiers in Cancer Science


FOR IMMEDIATE RELEASE
2017-12-06

ORCHARD PARK, New York - (Dec. 6, 2017) - Oncotarget, the world's largest oncology peer-reviewed research publication, awarded travel grants enabling four biomedical researchers to attend November's Frontiers in Cancer Science 2017 (FCS 2017) conference in Singapore. The travel sponsorship encourages the discussion of cancer discoveries in support of Oncotarget's commitment to maximizing the circulation of scientific research.

"We're dedicated to the wide dissemination of scientific advances... continue reading >>



Oncotarget: Researchers identify a potential molecular trigger for invasiveness in prostate cancer cells


FOR IMMEDIATE RELEASE
2017-11-20

The cover for issue 58 of Oncotarget features Figure 2C, "Representative confocal imaging of PC-3U cells treated with TGFβ for the indicated time periods," from Gudey, et al.

ORCHARD PARK, New York - (Nov. 20, 2017) - A small protein modification can trigger the aggressive migratory and invasive properties of prostate cancer cells, according to new research published on the cover of Oncotarget. The findings give greater insight into how cancers can move from one location in the body to... continue reading >>



Oncotarget: Researchers identify potential therapeutic target in aggressive breast cancer cells


FOR IMMEDIATE RELEASE
2017-11-15

The cover for issue 57 of Oncotarget features Figure 5A, "Ingenuity pathway analysis was performed using microarray data of E2 regulated genes in MDA-MB-231-ERβ cells following 5 days of treatment and revealed suppression of a cell cycle related network," from Reese, et al.

ORCHARD PARK, New York - (November 15, 2017) - An especially aggressive breast cancer cell can respond to hormone therapy if they express a specific protein known as estrogen receptor beta (ERβ), according to new research... continue reading >>



New Oncotarget Podcast Launched Today


FOR IMMEDIATE RELEASE
2017-11-08
Podcast will Extend Reach of Oncotarget to Professional Scientists and the Public

FOR IMMEDIATE RELEASE - ORCHARD PARK, New York - (November 8, 2017) - Oncotarget, the world′s largest oncology peer-reviewed research publication, is set to extend its reach with a series of podcasts that will allow scientists to delve deeper into a variety of research contributions found in the journal.

Subscribers to the new podcast series will gain access to the journal′s most important discoveries through full... continue reading >>



Researchers identify novel therapeutic strategy for drug-resistant thyroid cancers


FOR IMMEDIATE RELEASE
2017-10-18

The cover for issue 49 of Oncotarget features Figures 3 and 6, "Combined therapy with vemurafenib and palbociclib induced thyroid tumor cell death in both naïve and resistant clones, overcoming resistance to single-agent treatments," from Antonello, et al.

A video interview with the corresponding author and an audio version of this research article is also available online.

ORCHARD PARK, New York - (October 18, 2017) - Perhaps the only thing more devastating than being diagnosed with cancer... continue reading >>



Individuals in the US diagnosed with cancer are 2.7 times more likely to declare bankruptcy, than individuals without cancer, study finds


FOR IMMEDIATE RELEASE
2017-09-27

The cover for issue 42 of Oncotarget features Figure 3, "Comparable affordability of 8 patented cancer drugs in 7 countries," from Goldstein, et al.

An audio version of this research article is also available online

ORCHARD PARK, New York - (September 27, 2017) - As advancements in cancer therapies have been making headlines in recent years, cancer drug prices have significantly increased. The remaining question is, what are the economic impacts of the differentiations in cost of FDA approved... continue reading >>




Copyright © 2020 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC